Table 1.
Patient characteristics at baseline
| Baseline characteristics | No. of patients (n = 59) | % |
|---|---|---|
| Age at assignment, years | ||
| Median | 66.0 | |
| Range | 51–83 | |
| Gender | ||
| Females | 35 | 59% |
| Males | 24 | 41% |
| ECOG performance score | ||
| 0 | 45 | 76% |
| 1 | 14 | 24% |
| Time from initial diagnosis, months | ||
| Median | 2,0 | |
| Range | 0–70 | |
| Ann Arbor classification, stage | ||
| I | 0 | |
| II | 12 | 20% |
| III | 26 | 44% |
| IV | 21 | 36% |
| Bulky disease at least 5 cm | 18 | 31% |
| Bone marrow infiltration | ||
| 0% | 37 | 63% |
| 1–10% | 6 | 10% |
| 11–25% | 16 | 27% |
| Grade REAL/WHO | ||
| 1 | 22 | 37% |
| 2 | 22 | 37% |
| 2/3a | 3 | 5% |
| 3a | 11 | 19% |
| Not classified | 1 | 2% |
| LDH > upper limit of normal | 15 | 25% |
| FLIPI score | ||
| Low (≤ 1) | 18 | 31% |
| Intermediate (2) | 25 | 42% |
| High (> 2) | 16 | 27% |
Percentages are based on patients treated (n = 59) unless otherwise indicated
ECOG, Eastern Cooperative Oncology Group; FLIPI, Follicular Lymphoma International Prognostic Index; LDH, lactate dehydrogenase; REAL, Revised European-American Lymphoma [classification]; WHO, World Health Organization [classification of lymphoid neoplasias 2016]